Friday, December 2, 2016

BRIEF-Shire says topline results of Phase 3 investigational study of Vonvendi meets primary endpoint

* Topline results of Phase 3 investigational study of

Vonvendi [von Willebrand factor (recombinant)] meets primary

endpoint effectively controlling bleeding and blood loss during

surgical procedures

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)